Late-stage oncology trials face some of the most pressing challenges in drug development. Sites are often overwhelmed, patient eligibility requirements are increasingly complex and competition for both sites and participants continues to grow. Overcoming these hurdles demands innovative approaches that place the patient journey at the center of planning and execution.
This webinar will feature perspectives on rethinking site selection, feasibility and patient recruitment in ways that better align with the realities of modern oncology research. The featured speakers will explore how a paradigm shift in site selection methodology can open new opportunities for accessing the right patients, and how diagnostics, biomarkers and real-world considerations influence both recruitment and retention. In addition, the discussion will highlight strategies for reducing site burden and strengthening partnerships through training, streamlined processes and the integration of decentralized elements.
Through practical insights, attendees will gain a forward-looking perspective on how oncology trials can evolve to improve efficiency and patient outcomes in a highly competitive landscape.
Register for this webinar to learn how smarter site feasibility strategies can improve patient access and enrollment in oncology trials.
Speakers
Sandra Olthof, MSc (Biomedical Science), Global Operations Head, Oncology/Hematology, Allucent
Sandra Olthof, MSc (Biomedical Science), is the Global Operations Head of Oncology/Hematology at Allucent, where she leads cross-functional project teams, manages oncology and hematology portfolios and drives process optimization and client satisfaction within Clinical Trial Operations. With over 15 years of experience in clinical oncology, she has successfully led global Phase I–IV trials across immuno-oncology and hematologic oncology, ensuring operational excellence and high-quality delivery.
Almenia Garvey, Senior Director, Global Feasibility/Site Engagement, Allucent
Almenia Garvey is the Senior Director of Global Feasibility/Site Engagement at Allucent. With over 25 years of experience in clinical research, Almenia has been involved in numerous projects that integrate healthcare and technology, such as EHR2EDC. Her expertise lies in site selection strategy, investigator identification and investigator relationship management. Almenia serves on the Board of Directors for Nvolve, a non-profit organization dedicated to preparing young women for STEM careers. Additionally, she contributes her expertise as an advisory board member for CISCRP (Center for Information & Study on Clinical Research Participation).
Alex Hartnagel, MSc (Health Science), Senior Director, Project Management, Allucent
Alex Hartnagel, MSc (Health Science), is the Senior Director of Project Management at Allucent, with more than 25 years of experience in clinical research in the pharmaceutical and device industry. As Senior Director of Project Management, he oversees operational project teams, customer satisfaction and continuous improvement of processes within the Global Project Leadership Department. In his position, he controls and monitors the quality and full-service delivery of clinical trial project management activities.
Alex brings a deep understanding of all aspects of the clinical trial process, while maintaining a strong customer focus and sense of urgency. Alex has worked on multiple indications, with a strong background in infectious disease and immunology & oncology projects.
Almenia Garvey, Senior Director, Global Feasibility/Site Engagement, Allucent
Almenia Garvey is the Senior Director of Global Feasibility/Site Engagement at Allucent. With over 25 years of experience in clinical research, Almenia has been involved in numerous projects that integrate healthcare and technology, such as EHR2EDC. Her expertise lies in site selection strategy, investigator identification and investigator relationship management. Almenia serves on the Board of Directors for Nvolve, a non-profit organization dedicated to preparing young women for STEM careers. Additionally, she contributes her expertise as an advisory board member for CISCRP (Center for Information & Study on Clinical Research Participation).
What You Will Learn?
Attendees will gain insights into:
- How a patient pathway-focused approach can improve site selection in late-stage oncology trials
- Strategies to overcome challenges in oncology patient recruitment and retention
- Best practices for reducing site burden and strengthening site partnerships
- Practical insights into how late-stage oncology trials can evolve to drive greater efficiency
Who Should Attend?
This webinar will appeal to VPs, Directors, Managers and Heads involved in:
- Research and Development (R&D)
- Clinical Project Management/Trial Oversight
- Clinical Operations/Clinical Research
- Medical Affairs/Medical Writing/Pharmacovigilance
- Biostatistics and Data Science
- Regulatory Affairs/Strategy
- Chief Medical Officers (CMOs) and CEOs of small and medium-sized biotech/pharmaceutical companies
Share This
